Nonantimicrobial effects of tetracyclines;Efectos no antimicrobianos de las tetraciclinas

Revista Espanola de Quimioterapia

Volumn 23, Issue 1, 2010, Pages 4-11

  García Álvarez, Lara ^a   Oteo, José Antonio ^a  

^a CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

Author keywords

Cancer and inflammation; Metalloproteinases; Tetracyclines

Indexed keywords

DOXYCYCLINE; INCYCLINIDE; MATRIX METALLOPROTEINASE; MINOCYCLINE; TETRACYCLINE DERIVATIVE;

ABDOMINAL AORTA ANEURYSM; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; BONE METABOLISM; BREATHING; BRONCHIECTASIS; CARDIOVASCULAR DISEASE; CHEMISTRY; CHRONIC BRONCHITIS; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HUMAN; HUNTINGTON CHOREA; KAPOSI SARCOMA; KIDNEY ISCHEMIA; METASTASIS INHIBITION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OSTEOPOROSIS; PARKINSON DISEASE; PERIODONTITIS; PITYRIASIS LICHENOIDES; PYODERMA GANGRENOSUM; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; ROSACEA; SARCOIDOSIS; SUPPURATIVE HIDRADENITIS;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; MATRIX METALLOPROTEINASES; NERVOUS SYSTEM DISEASES; PROTEASE INHIBITORS; RESPIRATORY TRACT DISEASES; RHEUMATIC DISEASES; TETRACYCLINES;

EID: 77956500650     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65:232-260.
2. Nelson M.L. Chemical and biological dynamics of tetracyclines. Adv Dent Res1998; 12:5-11.
3. Kasbekar N. Tigecycline: A new glycylcycline antimicrobial agent. Am J Health Syst Pharm 2006; 63:1235-1243.
4. Garrelts JC, Schroeder T. Tigecycline: place in therapy and important considerations. Am J Health Syst Pharm. 2006; 63:1233.
5. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54:258-265.
6. Zakeri B, Wright GD. Chemical biology of tetracycline antibiotics. Biochem Cell Biol 2008; 86:124-136.
7. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93:178-193.
8. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum 1999; 42:1140-1146.
9. Collen A, Hanemaaijer R, Lupu F, Quax PH, van Lent N, Grimbergen J, et al. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood 2003; 101:1810-1817.
10. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002; 98:297-309.
11. Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, et al. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 2004; 10: 6512-6521.
12. Hanemaaijer R, Visser H, Koolwijk P, Sorsa T, Salo T, Golub LM, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 1998; 12:114-118
13. Soory M. A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review. Open Dent J 2008; 2:5-12.
14. Fife RS, Sledge GW Jr, Sissons S, Zerler B. Effects of tetracyclines on angiogenesis in vitro. Cancer Lett 2000; 153:75-78
15. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991; 51:672-675.
16. Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY. Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res 2004; 95:364-371.
17. Hoyt JC, Ballering J, Numanami H, Hayden JM, Robbins RA. Doxycycline modulates nitric oxide production in murine lung epithelial cells. J Immunol 2006; 176:567-572.
18. Gueders MM, Bertholet P, Perin F, Rocks N, Maree R, Botta V, et al. A novel formulation of inhaled doxycycline reduces allergeninduced inflammation, hyperresponsiveness and remodeling by matrix metalloproteinases and cytokines modulation in a mouse model of asthma. Biochem Pharmacol 2008; 75:514-526.
19. Kielian T, Esen N, Liu S, Phulwani NK, Syed MM, Phillips N, et al. Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess. Am J Pathol 2007; 171:1199-1214
20. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009; 196:168-179.
21. Vernillo AT, Rifkin BR. Effects of tetracyclines on bone metabolism. Adv Dent Res 1998; 12:56-62.
22. Payne JB, Stoner JA, Nummikoski PV, Reinhardt RA, Goren AD, Wolff MS, et al. Subantimicrobial dose doxycycline effects on alveolar bone loss in post-menopausal women. J Clin Periodontol 2007; 34:776-787.
23. Bezerra MM, Brito GA, Ribeiro RA, Rocha FA. Low-dose doxycycline prevents inflammatory bone resorption in rats. Braz J Med Biol Res 2002; 35:613-616.
24. Holmes SG, Still K, Buttle DJ, Bishop NJ, Grabowski PS. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors. Bone 2004; 35:471-478.
25. Franklin IJ, Harley SL, Greenhalgh RM, Powell JT. Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis. Br J Surg 1999; 86:771-775.
26. Ryan ME, Ramamurthy NS, Golub LM. Tetracyclines inhibit protein glycation in experimental diabetes. Adv Dent Res 1998;12:152-158.
27. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39:971-974.
28. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12:12-26.
29. Joshi RK, Atukorala DN, Abanmi A, al Khamis O, Haleem A. Successful treatment of Sweet's syndrome with doxycycline. Br J Dermatol 1993; 128:584-586
30. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001; 21:2580-2588.
31. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001; 166:7527-7533.
32. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001; 137:69-73.
33. Miyazaki E, Ando M, Fukami T, Nureki S, Eishi Y, Kumamoto T. Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect? Clin Rheumatol 2008; 27:1195-1197.
34. Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002; 20:153-159.
35. Loo WJ, Kirtschig G, Wojnarowska F. Minocycline as a therapeu-tic option in bullous pemphigoid. Clin Exp Dermatol 2001; 26:376-379.
36. Kelly KJ, Sutton TA, Weathered N, Ray N, Caldwell EJ, Plotkin Z, et al. Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2004; 287:F760-6.
37. Sewell KL, Breedveld F, Furrie E, O'Brien J, Brinckerhoff C, Dynesius- Trentham R, et al. The effect of minocycline in rat models of inflammatory arthritis: correlation of arthritis suppression with enhanced T cell calcium flux. Cell Immunol 1996;167:195-204.
38. Tilley BC, Alarcón GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995; 122:81-89.
39. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996; 93:14014-14019.
40. Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci 2007; 259:79-84.
41. O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum 2006; 54:621-627.